Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Coherus Oncology (CHRS) Stock Falls -62% Over 30 Days on Liquidity Pressures

Coherus Oncology (CHRS) Stock Falls -62% Over 30 Days on Liquidity Pressures

Key Takeaways

  • CHRS shares have fallen roughly 62% over the past 30 days, sliding from about $1.02 to near $0.39 as liquidity and dilution concerns intensified.
  • The selloff accelerated after third-quarter results, which included a revenue miss, lowered full-year LOQTORZI guidance, and a going-concern disclosure.
  • Management announced a roughly 30% workforce reduction and narrowed pipeline focus, lowering the quarterly LOQTORZI revenue needed to cover core costs to $25–$30 million.
  • LOQTORZI (toripalimab-tpzi) remains the company's only marketed product; third-quarter net sales rose 25% year over year but just 3% sequentially.
  • Encouraging tagmokitug plus toripalimab data in second-line esophageal cancer offered a pipeline offset but did not ease near-term balance-sheet worries.
  • For more detail on the company's outlook, explore CHRS Price Targets, Earnings, and Forecast pages.
  • Investors can also explore Trending AI Robots to see how AI-driven trading strategies are positioned across the market.

Coherus Oncology (CHRS) Business Focus and Current Standing

Coherus Oncology, formerly known as Coherus BioSciences, is a U.S.-based commercial-stage biopharmaceutical company focused on immuno-oncology. Founded in 2010 and led by Chief Executive Officer Denny Lanfear, the company has moved away from its legacy biosimilar business—divesting products such as UDENYCA, Cimerli, and Yusimry—to concentrate on cancer immunotherapies. Its lead commercial asset is LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor approved for nasopharyngeal carcinoma. The clinical pipeline is anchored by tagmokitug, an investigational anti-CCR8 antibody, and casdozokitug, an anti-IL-27 antibody. Investors follow CHRS primarily for LOQTORZI's commercial ramp and the pipeline's clinical readouts, balanced against a cash-constrained balance sheet and execution risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Coherus Oncology (CHRS) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CHRS has declined from approximately $1.02 to near $0.39, a drop of roughly 62%. Most of the move was concentrated in early-to-mid November following the company's third-quarter report. The longer-term trend is even steeper: shares traded near $1.32 in mid-August and now sit near $0.39, a decline of about 71% over the trailing quarter. The stock has been in a sustained downtrend through 2026, well below its 52-week high near $2.62, as persistent cash burn and financing overhang have outweighed clinical progress.

What Drove CHRS Stock Price in the Last 30 Days

The sharp decline was triggered by the company's third-quarter 2026 results, reported in early November. Coherus posted a non-GAAP loss of $0.20 per share on revenue of $14.27 million, short of the roughly $15.9 million consensus, with LOQTORZI net sales of $14.0 million. Management cut full-year LOQTORZI guidance to $54–$57 million from $57–$62 million and disclosed going-concern language in its quarterly filing, noting a cash runway of less than 12 months. Cash and investments fell to $83.6 million from $105.3 million at the end of the second quarter and $172.1 million at year-end. To preserve capital, the company announced a roughly 30% workforce reduction, from about 140 to 100 employees, expected to save $6–$7 million per quarter, and refinanced its term loan, adding about $11.5 million in net cash. A $50 million at-the-market equity program established in August added to dilution concerns. Positive tagmokitug plus toripalimab data in second-line esophageal cancer—a 33.3% confirmed response rate—provided a clinical bright spot, but the balance-sheet narrative dominated investor sentiment.

What Drove CHRS Stock Performance Over the Last Quarter

The quarterly decline reflects a broader multi-month story of tightening liquidity. With LOQTORZI as its only marketed product and quarterly sales still well below breakeven, Coherus has relied on cost cuts and financing to extend its runway. Over the quarter, the company trimmed expenses, narrowed its pipeline toward esophageal cancer, and sought capital through equity and debt transactions. Although clinical signals from tagmokitug and casdozokitug kept the long-term thesis alive, repeated financing steps, missed revenue expectations, and the going-concern disclosure progressively reset the stock's valuation lower.

CHRS Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor several factors that could shape CHRS going forward. LOQTORZI's commercial execution is central, with management targeting roughly $15 million in fourth-quarter revenue and a path toward a $25–$30 million quarterly breakeven. Regulatory developments are also key: Coherus plans to meet with the FDA on tagmokitug dosing and a second-line esophageal cancer study design, with potential for an expedited or accelerated approval pathway. Balance-sheet items remain critical, including potential ex-U.S. partnering for tagmokitug, UDENYCA divestiture milestone payments, and any additional financing. With the stock trading below $1, listing-compliance considerations and ongoing cash-burn trends will also remain in focus. From what I see, I’m watching this closely as these elements could influence the next moves.

Exploring AI Tools for Market Analysis

In my analysis of stocks like CHRS, I often turn to Tickeron’s AI Trading Bots to test how automated strategies might respond to similar situations. These tools help review performance across various market conditions and can offer additional perspectives on trading approaches without replacing individual judgment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CHRS

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


Momentum Indicator for CHRS turns negative, indicating new downward trend

CHRS saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 77 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CHRS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.596). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of biologic therapeutics for oncology and inflammatory diseases

Industry Biotechnology

Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
147
Web
https://www.coherus.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.